Vanguard Group Inc Has $2.33 Million Stake in Matinas BioPharma Holdings Inc (MTNB)

Vanguard Group Inc lowered its stake in Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) by 0.6% during the third quarter, according to the …

Matinas BioPharma logoVanguard Group Inc lowered its stake in Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) by 0.6% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,533,333 shares of the company’s stock after selling 16,076 shares during the quarter. Vanguard Group Inc owned about 2.25% of Matinas BioPharma worth $2,331,000 at the end of the most recent reporting period.

Separately, K.J. Harrison & Partners Inc acquired a new position in shares of Matinas BioPharma in the 3rd quarter valued at $150,000.

Several brokerages recently commented on MTNB. Maxim Group raised their price objective on Matinas BioPharma from $2.00 to $5.00 and gave the stock a “buy” rating in a research note on Monday, November 12th. Roth Capital began coverage on Matinas BioPharma in a research note on Monday, February 11th. They set a “buy” rating and a $4.75 price objective on the stock.

MTNB stock opened at $1.05 on Friday. Matinas BioPharma Holdings Inc has a 1 year low of $0.32 and a 1 year high of $1.48.

TRADEMARK VIOLATION WARNING: This report was originally published by Fairfield Current and is the sole property of of Fairfield Current. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://www.fairfieldcurrent.com/news/2019/02/16/vanguard-group-inc-has-2-33-million-stake-in-matinas-biopharma-holdings-inc-mtnb.html.

Matinas BioPharma Company Profile

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable.

Featured Story: Trading Strategy Methods and Types

Want to see what other hedge funds are holding MTNB?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB).

Institutional Ownership by Quarter for Matinas BioPharma (NYSEAMERICAN:MTNB)

Receive News & Ratings for Matinas BioPharma Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Matinas BioPharma and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Norwood Financial Co. (NASDAQ:NWFL) Position Raised by Vanguard Group Inc

Vanguard Group Inc increased its position in Norwood Financial Co. (NASDAQ:NWFL) by 6.4% in the 3rd quarter, according to its most recent …

Norwood Financial logoVanguard Group Inc increased its position in Norwood Financial Co. (NASDAQ:NWFL) by 6.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 198,849 shares of the financial services provider’s stock after buying an additional 12,005 shares during the quarter. Vanguard Group Inc owned 3.17% of Norwood Financial worth $7,787,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently added to or reduced their stakes in the business. Rhumbline Advisers acquired a new position in shares of Norwood Financial in the 3rd quarter valued at about $219,000. Bridgeway Capital Management Inc. grew its position in Norwood Financial by 21.1% in the third quarter. Bridgeway Capital Management Inc. now owns 17,249 shares of the financial services provider’s stock worth $675,000 after acquiring an additional 3,000 shares during the period. Renaissance Technologies LLC lifted its stake in Norwood Financial by 5.5% during the second quarter. Renaissance Technologies LLC now owns 36,450 shares of the financial services provider’s stock worth $1,313,000 after purchasing an additional 1,899 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Norwood Financial by 18.3% in the second quarter. Dimensional Fund Advisors LP now owns 56,502 shares of the financial services provider’s stock valued at $2,035,000 after acquiring an additional 8,746 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in Norwood Financial by 6.4% in the third quarter. Vanguard Group Inc. now owns 198,849 shares of the financial services provider’s stock valued at $7,787,000 after buying an additional 12,005 shares during the last quarter. 18.09% of the stock is owned by institutional investors and hedge funds.

In related news, COO Robert J. Mancuso acquired 1,000 shares of the company’s stock in a transaction on Monday, November 19th. The shares were acquired at an average cost of $37.00 per share, for a total transaction of $37,000.00. Following the purchase, the chief operating officer now owns 6,111 shares in the company, valued at $226,107. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Joseph W. Adams bought 1,030 shares of Norwood Financial stock in a transaction dated Thursday, January 24th. The shares were acquired at an average cost of $29.34 per share, for a total transaction of $30,220.20. Following the completion of the purchase, the director now directly owns 35,277 shares of the company’s stock, valued at approximately $1,035,027.18. The disclosure for this purchase can be found here. In the last three months, insiders bought 2,430 shares of company stock worth $79,012. 6.40% of the stock is currently owned by insiders.

Shares of NASDAQ:NWFL opened at $31.25 on Friday. Norwood Financial Co. has a 52 week low of $28.08 and a 52 week high of $40.58. The company has a debt-to-equity ratio of 0.31, a current ratio of 0.84 and a quick ratio of 0.84. The company has a market capitalization of $195.91 million, a P/E ratio of 14.10 and a beta of 0.21.

Norwood Financial (NASDAQ:NWFL) last issued its quarterly earnings results on Thursday, January 24th. The financial services provider reported $0.53 earnings per share for the quarter. Norwood Financial had a net margin of 27.54% and a return on equity of 11.84%. The firm had revenue of $11.03 million during the quarter.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, February 1st. Stockholders of record on Tuesday, January 15th were given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 3.07%. The ex-dividend date was Monday, January 14th. This is a positive change from Norwood Financial’s previous quarterly dividend of $0.22.

Separately, ValuEngine downgraded shares of Norwood Financial from a “hold” rating to a “sell” rating in a research report on Wednesday, December 5th.

WARNING: “Norwood Financial Co. (NASDAQ:NWFL) Position Raised by Vanguard Group Inc” was posted by Fairfield Current and is the sole property of of Fairfield Current. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at https://www.fairfieldcurrent.com/news/2019/02/16/vanguard-group-inc-has-7-79-million-holdings-in-norwood-financial-co-nwfl.html.

About Norwood Financial

Norwood Financial Corp. operates as the bank holding company for Wayne Bank that provides various banking products and services. It accepts a range of deposit products, such as interest-bearing and non-interest bearing transaction accounts, and statement savings and money market accounts, as well as certificate of deposits and individual retirement accounts.

See Also: Price to Earnings Ratio (PE) Basics

Institutional Ownership by Quarter for Norwood Financial (NASDAQ:NWFL)

Receive News & Ratings for Norwood Financial Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Norwood Financial and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Vanguard Group Inc. Has $48.68 Million Position in MacroGenics Inc (MGNX)

Vanguard Group Inc. raised its holdings in MacroGenics Inc (NASDAQ:MGNX) by 7.9% in the third quarter, according to its most recent 13F filing with …

MacroGenics logoVanguard Group Inc. raised its holdings in MacroGenics Inc (NASDAQ:MGNX) by 7.9% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,270,541 shares of the biopharmaceutical company’s stock after purchasing an additional 165,937 shares during the period. Vanguard Group Inc. owned approximately 5.37% of MacroGenics worth $48,680,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. BlackRock Inc. lifted its holdings in shares of MacroGenics by 17.5% during the 2nd quarter. BlackRock Inc. now owns 3,122,067 shares of the biopharmaceutical company’s stock worth $64,472,000 after acquiring an additional 465,948 shares during the period. Bank of America Corp DE lifted its holdings in shares of MacroGenics by 41.8% during the 2nd quarter. Bank of America Corp DE now owns 36,239 shares of the biopharmaceutical company’s stock worth $748,000 after acquiring an additional 10,685 shares during the period. Northern Trust Corp lifted its holdings in shares of MacroGenics by 18.5% during the 2nd quarter. Northern Trust Corp now owns 513,756 shares of the biopharmaceutical company’s stock worth $10,609,000 after acquiring an additional 80,233 shares during the period. Strs Ohio lifted its holdings in shares of MacroGenics by 24.9% during the 3rd quarter. Strs Ohio now owns 39,600 shares of the biopharmaceutical company’s stock worth $849,000 after acquiring an additional 7,900 shares during the period. Finally, Alps Advisors Inc. lifted its holdings in shares of MacroGenics by 22.0% during the 3rd quarter. Alps Advisors Inc. now owns 74,742 shares of the biopharmaceutical company’s stock worth $1,602,000 after acquiring an additional 13,500 shares during the period. 87.47% of the stock is owned by hedge funds and other institutional investors.

In related news, Director Matthew K. Fust sold 6,924 shares of the business’s stock in a transaction that occurred on Wednesday, February 6th. The shares were sold at an average price of $29.38, for a total transaction of $203,427.12. Following the completion of the transaction, the director now owns 7,424 shares of the company’s stock, valued at $218,117.12. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Thomas Spitznagel sold 1,770 shares of MacroGenics stock in a transaction that occurred on Wednesday, February 6th. The shares were sold at an average price of $30.00, for a total transaction of $53,100.00. Following the sale, the senior vice president now owns 1,770 shares of the company’s stock, valued at $53,100. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 8,762 shares of company stock valued at $258,567. 8.82% of the stock is owned by corporate insiders.

MGNX has been the subject of a number of recent analyst reports. Citigroup downgraded shares of MacroGenics from a “neutral” rating to a “sell” rating and cut their price target for the stock from $22.00 to $10.00 in a report on Monday, February 4th. Wedbush reaffirmed a “positive” rating and set a $20.00 price target (down previously from $44.00) on shares of MacroGenics in a report on Tuesday, January 22nd. They noted that the move was a valuation call. HC Wainwright reaffirmed a “buy” rating and set a $34.00 price target on shares of MacroGenics in a report on Tuesday, October 30th. Raymond James downgraded shares of MacroGenics from an “outperform” rating to an “underperform” rating in a report on Monday, December 10th. Finally, ValuEngine cut shares of MacroGenics from a “buy” rating to a “hold” rating in a research report on Friday, October 26th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. MacroGenics has an average rating of “Buy” and an average target price of $31.78.

NASDAQ:MGNX traded up $0.62 during mid-day trading on Friday, hitting $21.74. 248,083 shares of the stock traded hands, compared to its average volume of 2,426,684. The stock has a market cap of $892.53 million, a P/E ratio of -40.26 and a beta of 2.65. MacroGenics Inc has a 12-month low of $9.87 and a 12-month high of $32.74.

COPYRIGHT VIOLATION NOTICE: This article was published by Fairfield Current and is owned by of Fairfield Current. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://www.fairfieldcurrent.com/news/2019/02/15/vanguard-group-inc-boosts-position-in-macrogenics-inc-mgnx.html.

MacroGenics Profile

MacroGenics, Inc, a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer primarily by modulating the human immune system, and autoimmune disorders and infectious diseases in the United States. The company’s advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers.

Read More: 52-Week High/Low Prices For Stock Selection

Institutional Ownership by Quarter for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for MacroGenics and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Dynex Capital Inc (NYSE:DX) Holdings Lifted by Vanguard Group Inc

Vanguard Group Inc lifted its holdings in Dynex Capital Inc (NYSE:DX) by 19.6% during the third quarter, according to its most recent 13F filing with the …

Dynex Capital logoVanguard Group Inc lifted its holdings in Dynex Capital Inc (NYSE:DX) by 19.6% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,329,780 shares of the real estate investment trust’s stock after buying an additional 544,936 shares during the period. Vanguard Group Inc owned approximately 5.58% of Dynex Capital worth $21,244,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Bank of America Corp DE grew its position in Dynex Capital by 77.1% in the second quarter. Bank of America Corp DE now owns 23,249 shares of the real estate investment trust’s stock worth $151,000 after acquiring an additional 10,120 shares in the last quarter. MetLife Investment Advisors LLC boosted its holdings in shares of Dynex Capital by 167.9% during the second quarter. MetLife Investment Advisors LLC now owns 27,274 shares of the real estate investment trust’s stock worth $178,000 after purchasing an additional 17,092 shares during the period. Los Angeles Capital Management & Equity Research Inc. boosted its holdings in shares of Dynex Capital by 40.9% during the third quarter. Los Angeles Capital Management & Equity Research Inc. now owns 52,837 shares of the real estate investment trust’s stock worth $337,000 after purchasing an additional 15,327 shares during the period. Acadian Asset Management LLC purchased a new stake in shares of Dynex Capital during the third quarter worth about $347,000. Finally, GWM Advisors LLC purchased a new stake in shares of Dynex Capital during the third quarter worth about $396,000. Hedge funds and other institutional investors own 48.28% of the company’s stock.

In other news, CEO Byron L. Boston acquired 17,000 shares of the firm’s stock in a transaction dated Thursday, January 31st. The shares were purchased at an average cost of $5.90 per share, for a total transaction of $100,300.00. Following the transaction, the chief executive officer now directly owns 611,545 shares of the company’s stock, valued at $3,608,115.50. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Stephen J. Benedetti purchased 10,000 shares of Dynex Capital stock in a transaction on Thursday, January 31st. The stock was bought at an average price of $5.90 per share, for a total transaction of $59,000.00. Following the completion of the acquisition, the chief financial officer now owns 277,387 shares in the company, valued at approximately $1,636,583.30. The disclosure for this purchase can be found here. Insiders have bought a total of 31,542 shares of company stock worth $186,098 in the last quarter. Corporate insiders own 3.96% of the company’s stock.

Shares of DX opened at $6.08 on Friday. The company has a market cap of $380.67 million, a P/E ratio of 8.33 and a beta of 0.61. The company has a quick ratio of 0.05, a current ratio of 0.05 and a debt-to-equity ratio of 0.01. Dynex Capital Inc has a twelve month low of $5.57 and a twelve month high of $6.82.

Dynex Capital (NYSE:DX) last announced its quarterly earnings results on Thursday, February 7th. The real estate investment trust reported $0.18 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.19 by ($0.01). Dynex Capital had a net margin of 6.38% and a return on equity of 14.06%. The firm had revenue of $12.96 million for the quarter. On average, sell-side analysts anticipate that Dynex Capital Inc will post 0.72 EPS for the current fiscal year.

The firm also recently declared a monthly dividend, which will be paid on Thursday, February 28th. Stockholders of record on Thursday, February 14th will be paid a dividend of $0.06 per share. This represents a $0.72 annualized dividend and a dividend yield of 11.84%. The ex-dividend date is Wednesday, February 13th. Dynex Capital’s dividend payout ratio is presently 32.88%.

A number of analysts have recently weighed in on the stock. Zacks Investment Research upgraded shares of Dynex Capital from a “hold” rating to a “buy” rating and set a $6.75 target price for the company in a report on Monday. TheStreet downgraded shares of Dynex Capital from a “c” rating to a “d+” rating in a research note on Friday, February 8th. Finally, ValuEngine raised shares of Dynex Capital from a “sell” rating to a “hold” rating in a research note on Tuesday, November 13th.

TRADEMARK VIOLATION WARNING: This news story was first posted by Fairfield Current and is the property of of Fairfield Current. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://www.fairfieldcurrent.com/news/2019/02/15/vanguard-group-inc-raises-holdings-in-dynex-capital-inc-dx.html.

Dynex Capital Profile

Dynex Capital, Inc, a mortgage real estate investment trust, invests in mortgage-backed securities (MBS) on a leveraged basis in the United States. It invests in agency and non-agency MBS consisting of residential MBS, commercial MBS (CMBS), and CMBS interest-only securities. Agency MBS have a guaranty of principal payment by an agency of the U.S.

Featured Article: Is it better to buy a fund with a higher or lower NAV?

Institutional Ownership by Quarter for Dynex Capital (NYSE:DX)

Receive News & Ratings for Dynex Capital Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Dynex Capital and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Fabrinet (NYSE:FN) Position Increased by Vanguard Group Inc.

Vanguard Group Inc. lifted its holdings in Fabrinet (NYSE:FN) by 1.6% during the third quarter, according to its most recent 13F filing with the …

Fabrinet logoVanguard Group Inc. lifted its holdings in Fabrinet (NYSE:FN) by 1.6% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,183,069 shares of the technology company’s stock after buying an additional 33,413 shares during the period. Vanguard Group Inc. owned approximately 5.93% of Fabrinet worth $100,988,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Csenge Advisory Group purchased a new position in Fabrinet in the third quarter worth $117,000. BlueMountain Capital Management LLC purchased a new stake in shares of Fabrinet during the third quarter worth about $111,000. Quantbot Technologies LP purchased a new stake in shares of Fabrinet during the third quarter worth about $110,000. C M Bidwell & Associates Ltd. purchased a new stake in shares of Fabrinet during the third quarter worth about $169,000. Finally, Boenning & Scattergood Inc. purchased a new stake in shares of Fabrinet during the third quarter worth about $222,000. Hedge funds and other institutional investors own 93.49% of the company’s stock.

In related news, COO Harpal Gill sold 33,479 shares of Fabrinet stock in a transaction dated Wednesday, November 28th. The shares were sold at an average price of $52.00, for a total transaction of $1,740,908.00. Following the completion of the transaction, the chief operating officer now directly owns 51,860 shares of the company’s stock, valued at approximately $2,696,720. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Toh-Seng Ng sold 30,000 shares of the business’s stock in a transaction dated Thursday, November 29th. The shares were sold at an average price of $52.70, for a total transaction of $1,581,000.00. Following the completion of the sale, the chief financial officer now directly owns 117,340 shares of the company’s stock, valued at $6,183,818. The disclosure for this sale can be found here. Insiders have sold a total of 93,479 shares of company stock worth $4,896,608 over the last 90 days. Insiders own 1.90% of the company’s stock.

A number of analysts have recently weighed in on the stock. Zacks Investment Research upgraded shares of Fabrinet from a “hold” rating to a “buy” rating and set a $63.00 target price for the company in a report on Friday, January 11th. Piper Jaffray Companies increased their price target on shares of Fabrinet from $56.00 to $61.00 and gave the stock an “overweight” rating in a research note on Thursday, January 24th. Needham & Company LLC reissued a “buy” rating and issued a $62.00 price target (up from $58.00) on shares of Fabrinet in a research note on Tuesday, December 18th. Finally, Stifel Nicolaus assumed coverage on shares of Fabrinet in a research note on Monday, October 22nd. They set a “buy” rating and a $53.00 target price for the company. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $53.17.

Shares of FN stock opened at $54.59 on Friday. Fabrinet has a 12-month low of $27.63 and a 12-month high of $58.24. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.26 and a current ratio of 3.19. The company has a market capitalization of $1.98 billion, a P/E ratio of 18.32, a P/E/G ratio of 1.22 and a beta of 0.61.

Fabrinet (NYSE:FN) last issued its quarterly earnings results on Monday, February 4th. The technology company reported $0.97 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.92 by $0.05. The business had revenue of $403.10 million for the quarter, compared to analysts’ expectations of $386.22 million. Fabrinet had a net margin of 7.08% and a return on equity of 14.91%. The company’s revenue was up 19.6% compared to the same quarter last year. During the same quarter last year, the company posted $0.72 EPS. As a group, equities analysts predict that Fabrinet will post 3.24 EPS for the current year.

WARNING: This article was originally reported by Fairfield Current and is the property of of Fairfield Current. If you are viewing this article on another site, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The legal version of this article can be read at https://www.fairfieldcurrent.com/news/2019/02/15/fabrinet-fn-shares-bought-by-vanguard-group-inc.html.

Fabrinet Company Profile

Fabrinet provides optical packaging and precision optical, electro-mechanical, and electronic manufacturing services in North America, the Asia-Pacific, and Europe. The company offers a range of optical and electro-mechanical capabilities in the manufacturing process, including process design and engineering, supply chain management, manufacturing, printed circuit board assembly, packaging, integration, final assembly, and test.

Featured Story: How Do You Calculate Return on Equity (ROE)?

Institutional Ownership by Quarter for Fabrinet (NYSE:FN)

Receive News & Ratings for Fabrinet Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Fabrinet and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts